Education
About Us
Working with TipRanks
Follow Us
Clever Leaves Holdings (CLVR)
OTHER OTC:CLVR
Top Page
Clever Leaves Holdings
(OTC:CLVR)
Rating:46Neutral
Price Target:―
Clever Leaves Holdings (CLVR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$175.00
Dividend YieldN/A
Average Volume (3M)670.00
Price to Earnings (P/E)―
Beta (1Y)102806.66
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees296
SectorHealthcare
Sector Strength39
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-9.73
Shares Outstanding1,754,795
10 Day Avg. Volume301
30 Day Avg. Volume670
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.39
Enterprise Value/Market Cap18.25K
Enterprise Value/Revenue0.05
Enterprise Value/Gross Profit0.49
Enterprise Value/Ebitda-0.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Clever Leaves Holdings Business Overview & Revenue Model
Company DescriptionClever Leaves Holdings Inc. (CLVR) is a multinational cannabis company engaged in the cultivation, extraction, manufacturing, and distribution of pharmaceutical-grade cannabinoids. Operating primarily in Latin America and North America, Clever Leaves focuses on the production of high-quality cannabis extracts and finished products, leveraging its large-scale cultivation facilities in Colombia and Portugal. The company is committed to advancing the medical cannabis industry through its innovative practices and adherence to stringent compliance standards.
How the Company Makes MoneyClever Leaves Holdings generates revenue through its diversified business model, which includes the sale of cannabis extracts, such as CBD and THC oils, as well as dried flower and finished goods to pharmaceutical companies, consumer brands, and other enterprises in the cannabis sector. The company capitalizes on its cost-effective production capabilities in Colombia and Portugal to offer competitive prices. Additionally, Clever Leaves engages in strategic partnerships and supply agreements with global entities to expand its market reach and enhance its product distribution. Revenue is further bolstered through its contract manufacturing services, where it offers expertise in formulating and producing cannabis-based products for third-party brands.
Clever Leaves Holdings Financial Statement Overview
Summary
Clever Leaves Holdings shows improved gross profit margins and reduced negative cash flow, but struggles with persistent net losses and negative cash flow. The balance sheet is strong with low leverage, but operational efficiencies need improvement to reach profitability.Income Statement
The company has shown a declining revenue trend from $17.8M in 2022 to $17.4M in 2023. The gross profit margin improved from 24.3% in 2022 to 37.6% in 2023, indicating better cost management. However, the company faces significant challenges with negative net profit and EBIT margins, reflecting ongoing profitability struggles.40
Negative
Balance Sheet
Clever Leaves Holdings has a low debt-to-equity ratio of 0.09, suggesting low financial leverage. However, the return on equity is negative due to net losses, implying a need for improved operational efficiency. The equity ratio of 77.5% in 2023 indicates a strong capital structure with substantial equity backing.55
Neutral
Cash Flow
The company experienced a significant reduction in negative free cash flow from -$30.37M in 2022 to -$11.54M in 2023. Despite this improvement, the negative operating cash flow to net income ratio highlights ongoing cash generation issues.35
Negative
| Breakdown | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.42M | 17.80M | 15.37M | 12.12M | 7.83M |
| Gross Profit | 6.56M | 4.33M | 6.81M | 7.41M | 3.10M |
| EBITDA | -16.84M | -35.80M | -35.19M | -23.26M | -41.72M |
| Net Income | -17.90M | -66.10M | -45.63M | -41.41M | -48.13M |
Balance Sheet | |||||
| Total Assets | 31.24M | 52.10M | 116.16M | 165.88M | 95.72M |
| Cash, Cash Equivalents and Short-Term Investments | 6.83M | 12.45M | 37.23M | 79.46M | 12.04M |
| Total Debt | 2.09M | 3.86M | 25.09M | 33.84M | 33.73M |
| Total Liabilities | 7.03M | 11.69M | 43.39M | 51.57M | 45.52M |
| Stockholders Equity | 24.22M | 40.41M | 72.77M | 114.31M | 45.50M |
Cash Flow | |||||
| Free Cash Flow | -11.54M | -30.37M | -43.51M | -25.63M | -55.73M |
| Operating Cash Flow | -11.51M | -29.07M | -36.23M | -21.96M | -37.05M |
| Investing Cash Flow | 4.69M | 1.19M | -7.28M | -3.67M | -33.90M |
| Financing Cash Flow | 656.00K | 3.29M | 1.83M | 91.84M | 62.83M |
Clever Leaves Holdings Risk Analysis
Clever Leaves Holdings disclosed 49 risk factors in its most recent earnings report. Clever Leaves Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We effected a one-for-thirty reverse share split of our common shares (the "Reverse Share Split"), in August 2023.The Reverse Share Split may adversely impact the liquidity of our common shares and warrants and may not be effective in facilitating our efforts to maintain compliance with the continued listing requirements of Nasdaq. Q4, 2023
2.
We may choose to delist our securities from Nasdaq and deregister under the Exchange Act, which could negatively affect the liquidity and trading prices of our common shares would result in substantially less disclosure about us and severely impair our ability to raise capital. Q4, 2023
3.
We may not be able to obtain import permits in the destination countries or export permits in Colombia in a timely manner or of the required quantities Q4, 2023
Clever Leaves Holdings Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | C$1.08B | 15.58 | 4.61% | ― | 38.16% | ― | |
61 Neutral | C$1.08B | 15.58 | 4.61% | ― | 38.16% | ― | |
54 Neutral | $319.07M | ― | -9.20% | ― | -3.02% | 26.00% | |
54 Neutral | $319.07M | ― | -9.20% | ― | -3.02% | 26.00% | |
52 Neutral | $7.45B | 0.30 | -61.93% | 2.28% | 16.62% | 1.04% | |
50 Neutral | $340.29M | 103.77 | 3.05% | ― | 16.39% | -98.10% | |
49 Neutral | $522.59M | ― | -31.06% | ― | 11.22% | -108.58% | |
46 Neutral | $175.00 | ― | -73.91% | ― | ― | ― | |
43 Neutral | $365.50M | ― | -122.10% | ― | -18.39% | 35.21% |
* Healthcare Sector Average
Performance Comparison
CLVR
Clever Leaves Holdings
0.02
-2.58
-99.23%
TLRY
Tilray
0.50
-1.26
-71.59%
SNDL
SNDL
1.24
-0.73
-37.06%
SNDL
SNDL
1.24
-0.73
-37.06%
TSE:WEED
Canopy Growth
1.66
-6.81
-80.40%
TSE:CRON
Cronos Group
2.79
-0.28
-9.12%
TSE:CRON
Cronos Group
2.79
-0.28
-9.12%
TSE:ACB
Aurora Cannabis
6.05
-1.24
-17.01%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.